TD Cowen Upgrades RXO to Hold, Raises Price Target to $30.25

TD Cowen analyst Jason Seidl has upgraded RXO from Sell to Hold and increased the price target from $17.50 to $30.25. This change reflects a more favorable outlook for the company in the market.